Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All ...

SAN DIEGO - DexCom , Inc. (NASDAQ:DXCM) shares fell 6% in after-hours trading on Thursday after the continuous glucose monitoring systems maker reported fourth-quarter earnings that missed analyst ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

Over the past decade, the rising cost of insulin epitomized the broader systemic issue of higher healthcare out-of-pocket ...

DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...